This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Calcium channel blockers in angina

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

There are three different groups of calcium channel blockers:

  • dihydropyridine group e.g. nifedipine. This group acts primarily as arterial vasodilators. They are effective in the management of angina - however side-effects such as flushing and tachycardia may be troublesome - particularly with short-acting preparations. There is some observational evidence that the use of high doses or short acting dihyropyridines may be associated with adverse morbidity and mortality. Although the evidence currently available falls short of proof, it appears prudent to use longer acting agents.
  • verapamil acts primarily to reduce the force of myocardial contraction and to limit heart rate. This drug is contraindicated in patients with ventricular impairment. Extreme caution is required if combining verapamil with a beta-blocker - in general this combination should be avoided.
  • diltiazem - has properties intermediate between verapamil and the dihydropyridines.

Mibefradil, a new class of calcium channel blocker with rate - limiting properties was withdrawn (1).

Reference:

  1. notification from Roche Products Ltd (5/6/98)
  2. Factfile (3/97). British Heart Foundation

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.